New York, USA – January 5, 2023 – CD BioSciences is a company focused on providing early discovery and development of preclinical studies, the team works closely and communicates actively to achieve common goals of helping researchers and professionals understand PC biology, explore new PC therapeutics and protocols, and develop new PC biomarkers. Based on tailored services, robust platforms, powerful analytics, and cross-platform collaborations, CD BioSciences announced the release of its full range of PC basic research to support drug development and delivery.
CD BioSciences is dedicated to helping researchers and professionals understand pancreatic cancer (PC) biology, discover new PC therapies and strategies, and develop new PC biomarkers. CD BioSciences now offers biological sample collection and processing, histology, immunostaining and imaging services to support basic and translational PC research projects. Based on advanced platforms and years of experience in the PC field, CD BioSciences is committed to providing customers with the best customization services to meet the specific needs of their projects. CD BioSciences can greatly improve customers’ understanding of PC pathology, provide superior quality specimen collection and processing, and lay the foundation for fruitful cancer research, including incoming sample processing, nucleic acid and protein extraction, electronic biological sample tracking.
CD BioSciences is committed to providing customers with optimized and personalized services to support PC preclinical research projects; focusing on PC cells, providing a series of PC cell research services, including PC cell line establishment and characterization, PC cell analysis and evaluation, PC cell Cell metabolism research, etc. CD BioSciences provides a single solution service for deriving CSCs from cancer cells. Based on a heterochromatin modulation approach to reprogram cancer cells by modulating chromatin structure using small molecule compounds, it provides sufficient numbers and relative stability of CSCs and facilitates the successful development of CSC-targeted therapeutic regimens for global customers.
“With many years of experience in PC genetic/molecular research, we can provide our clients with various quality services. We can design and plan experimental protocols according to the specific needs of customers, and provide suitable solutions to help your basic PC research or drug development projects,” said Marcia Brady, the marketing director of CD BioSciences. She also added, “Our aim is to apply state-of-the-art infrastructure and market-leading technologies to advance PC research and drug development.”
About CD BioSciences
CD BioSciences is a leading provider of pancreatic cancer research services. We have many years of experience in PC molecular research and can provide our customers with various high-quality services. Based on our advanced preclinical biomarker platform, we can help our global clients advance their progress in PC biomarker discovery and analysis.
Media Contact
Company Name: CD BioSciences
Contact Person: Marcia Brady
Email: Send Email
Phone: 1-631-372-1052
Country: United States
Website: https://www.pancrecancer.com